JDM  Vol.3 No.3 , August 2013
Addition of Metanx in pregabalin partial responders for painful diabetic neuropathy
Abstract: Objective: To study the effect of addition of Metanx on burning parasthesias in patients with symptomatic diabetic neuropathy who had obtained only partial symptom resolution with pregabalin. Research design and methods: This was an open-label pilot study. There were 16 patients (7 males, 9 females) in the study group and 8 patients (3 males, 5 females) in the control group. A patient numeric rating scale (0 - 10) of neuropathy associated pain was obtained at baseline and at 20 weeks. The control group continued on a fixed dosage of pregabalin (Lyrica) without additional medication, while the study group was supplemented with Metanx (L-methylfolate, methylcobalamin, and pyridoxal 5- phosphate), in addition to being continued on a fixed dosage of pregabalin. Results: After 20 weeks, patients in the study group experienced greater pain relief compared to the control group, (87.5% vs. 25% respectively, p = 0.005). The average pain score reduction after 20 weeks in the study group was 3 compared to0.25 inthe control group (p < 0.001). Conclusion: Our study suggested that addition of Metanx may be used for the relief of pain in patients that have obtained only partial resolution of symptomatology from pregabalin.
Cite this paper: Jacobs, A. and Cheng, D. (2013) Addition of Metanx in pregabalin partial responders for painful diabetic neuropathy. Journal of Diabetes Mellitus, 3, 134-138. doi: 10.4236/jdm.2013.33020.

[1]   Boulton, A.J., Vinik, A.I., Arezzo, J.C., et al. (2005) Diabetic neuropathies: A statement by the American Diabetes Association. Diabetes Care, 28, 956-962. doi:10.2337/diacare.28.4.956

[2]   Boulton, A.J., Vileikyte, L., Ragnarson-Tennvall, G. and Apelqvist, J. (2005) The global burden of diabetic foot disease. Lancet, 366, 1719-1724. doi:10.1016/S0140-6736(05)67698-2

[3]   Lesser, H., Sharma, U., LaMoreaux, L. and Poole, R.M. (2004) Pregabalin relieves symptoms of painful diabetic neuropathy: A randomized controlled trial. Neurology, 63, 2104-2110. doi:10.1212/01.WNL.0000145767.36287.A1

[4]   Argoff, C.E., Backonja, M.M., Belgrade, M.J., et al. (2006) Consensus guidelines: Treatment planning and options. Diabetic peripheral neuropathic pain. Mayo Clinic Proceedings, 81, S12-S25. doi:10.1016/S0025-6196(11)61474-2

[5]   Richter, R.W., Portenoy, R., Sharma, U., LaMoreaux, L., Bockbrader, H. and Knapp, L.E. (2005) Relief of painful diabetic peripheral neuropathy with pregabalin: A randomized, placebocontrolled trial. Journal of Pain, 6, 253-260. doi:10.1016/j.jpain.2004.12.007

[6]   Sadekov, R.A., Danilov, A.B. and Vein, A.M. (1999) Diabetic polyneuropathy treatment with Benfotimine. Arzneimittelforschung, 49, 220-224.

[7]   Yaqub, B.A., Siddique, A. and Sulimani, R. (1992) Effects of methylcobalamin on diabetic neuropathy. Clinical Neurology and Neurosurgery, 94, 105-111. doi:10.1016/0303-8467(92)90066-C

[8]   Walker, M. and Morris, L. (2007) Increased cutaneous sensibility in patients with diabetic neuropathy utilizing a pharmacological approach-clinical case evidence. Vascular Disease Management, 2, 1-8.

[9]   Walker Jr., M.J., Morris, L.M. and Cheng, D. (2010) Improvement of cutaneous sensitivity in diabetic peripheral neuropathy with combination L-methylfolate, methylcobalamin, and pyridoxal 5’-phosphate. Reviews in Neurological Diseases, 7, 132-139.

[10]   Head, K.A. (2006) Peripheral neuropathy: Pathogenic mechanisms and alternative therapies. Alternative Medicine Review, 11, 294-329.

[11]   Zhang, Y.F. and Ning, G. (2008) Mecobalamin. Expert Opinion on Investigational Drugs, 17, 953-964. doi:10.1517/13543784.17.6.953

[12]   American Diabetes Association (2008) Standards of medical care in diabetes—2008. Diabetes Care, 31, S12-S54. doi:10.2337/dc08-S012

[13]   Backonja, M., Beydoun, A., Edwards, K.R., et al. (1998) Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: A randomized controlled trial. Journal of the American Medical Association, 280, 1831-1836. doi:10.1001/jama.280.21.1831

[14]   Serpell, M.G. (2002) Gabapentin in neuropathic pain syndromes: A randomised, double-blind, placebo-controlled trial. Pain, 99, 557-566. doi:10.1016/S0304-3959(02)00255-5

[15]   Duby, J.J., Campbell, R.K., Setter, S.M., White, J.R. and Rasmussen, K.A. (2004) Diabetic neuropathy: An intensive review. American Journal of Health-System Pharmacy, 61, 160-173.

[16]   McQuay, H.J., Tramer, M., Nye, B.A., Carroll, D., Wiffen, P.J. and Moore, R.A. (1996) A systematic review of antidepressants in neuropathic pain. Pain, 68, 217-227. doi:10.1016/S0304-3959(96)03140-5

[17]   Goldstein, D.J., Lu, Y., Detke, M.J., Lee, T.C. and Iyengar, S. (2005) Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain, 116, 109-118. doi:10.1016/j.pain.2005.03.029

[18]   Sindrup, S.H., Bach, F.W., Madsen, C., Gram, L.F. and Jensen, T.S. (2003) Venlafaxine versus imipramine in painful polyneuropathy: A randomized, controlled trial. Neurology, 60, 1284-1289. doi:10.1212/01.WNL.0000058749.49264.BD

[19]   Gimbel, J.S., Richards, P. and Portenoy, R.K. (2003) Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology, 60, 927-934. doi:10.1212/01.WNL.000 0057720.36503.2C

[20]   Sindrup, S.H., Andersen, G., Madsen, C., Smith, T., Brosen, K. and Jensen, T.S. (1999) Tramadol relieves pain and allodynia in polyneuropathy: A randomised, double-blind, controlled trial. Pain, 83, 85-90. doi:10.1016/S0304-3959(99)00079-2

[21]   Ziegler, D., Ametov, A., Barinov, A., Dyck, P.J., Gurieva, I., Low, P.A., et al. (2006) Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: The Sydney 2 trial. Diabetes Care, 29, 2365-2370. doi:10.2337/dc06-1216

[22]   Bramswig, S. and Pietrzik, K. (2005) The relevance of selected vitamins (B-vitamins, vitamin C, vitamin E) in patients with type 2-diabetes. Aktuelle Ern?hrungsmedizin, 30, 311-322. doi:10.1055/s-2005-915301

[23]   Rosenstock, J., Tuchman, M., LaMoreaux, L. and Sharma, U. (2004) Pregabalin for the treatment of painful diabetic peripheral neuropathy: A double-blind, placebo-controlled trial. Pain, 110, 628-638. doi:10.1016/j.pain.2004.05.001

[24]   Ambrosch, A., Dierkes, J., Lobmann, R., Kuhne, W., Konig, W., Luley, C., et al. (2001) Relation between homocysteinaemia and diabetic neuropathy in patients with Type 2 diabetes mellitus. Diabetic Medicine, 18, 185-192. doi:10.1046/j.1464-5491.2001.00445.x

[25]   de Luis, D.A., Fernandez, N., Arranz, M.L., Aller, R., Izaola, O. and Romero, E. (2005) Total homocysteine levels relation with chronic complications of diabetes, body composition, and other cardiovascular risk factors in a population of patients with diabetes mellitus type 2. Journal of Diabetes and Its Complications, 19, 42-46. doi:10.1016/j.jdiacomp.2003.12.003

[26]   Guttormsen, A.B., Ueland, P.M., Svarstad, E. and Refsum, H. (1997) Kinetic basis of hyperhomocysteinemia in patients with chronic renal failure. Kidney International, 52, 495-502. doi:10.1038/ki.1997.359

[27]   Stabler, S.P., Estacio, R., Jeffers, B.W., Cohen, J.A., Allen, R.H. and Schrier, R.W. (1999) Total homocysteine is associated with nephropathy in non-insulin-dependent diabetes mellitus. Metabolism, 48, 1096-1101. doi:10.1016/S0026-0495(99)90121-X

[28]   Obeid, R., McCaddon, A. and Herrmann, W. (2007) The role of hyperhomocysteinemia and B vitamin deficiency in neurological and psychiatric diseases. Clinical Chemistry and Laboratory Medicine, 45, 1590-1606. doi:10.1515/CCLM.2007.356

[29]   Scalabrino, G., Buccellato, F.R., Veber, D. and Mutti, E. (2003) New basis of the neurotrophic action of vitamin B12. Clinical Chemistry and Laboratory Medicine, 41, 1435-1437. doi:10.1515/CCLM.2003.220

[30]   Wile, D.J. and Cory, T. (2010) Association of metformin, elevated homocysteine, and methylmalonic acid levels and clinically worsened diabetic peripheral neuropathy. Diabetes Care, 33, 156-161. doi:10.2337/dc09-0606

[31]   Kikuchi, M., Kashii, S., Honda, Y., Tamura, Y., Kaneda, K. and Akaike, A. (1997) Protective effects of methylcobalamin, a vitamin B12 analog, against glutamate-induced neurotoxicity in retinal cell culture. Investigative Ophthalmology & Visual Science, 38, 848-854.

[32]   Watanabe, T., Kaji, R., Oka, N., Bara, W. and Kimura, J. (1994) Ultra-high dose methylcobalamin promotes nerve regeneration in experimental acrylamide neuropathy. Journal of the Neurological Sciences, 122, 140-143. doi:10.1016/0022-510X(94)90290-9

[33]   Lonn, E., Yusuf, S., Arnold, M.J., Sheridan, P., Pogue, J., Micks, M., et al. (2006) Homocysteine lowering with folic acid and B vitamins in vascular disease. The New England Journal of Medicine, 354, 1567-1577. doi:10.1056/NEJMoa060900

[34]   Mangoni, A.A., Sherwood, R.A., Asonganyi, B., Swift, C.G., Thomas, S. and Jackson, S.H. (2005) Short term oral folic acid supplementation enhances endothelial function in patients with type 2 diabetes. American Journal of Hypertension, 18, 220-226. doi:10.1016/j.amjhyper.2004.08.036

[35]   Venn, B.J., Green, T.J., Moser, R. and Mann, J.I. (2003) Comparison of the effect of low-dose supplementation with L-5-methyltetrahydrofolate or folic acid on plasma homocysteine: A randomized placebo-controlled study. The American Journal of Clinical Nutrition, 77, 658-662.

[36]   Jones, C.L. and Gonzalez, V. (1978) Pyridoxine deficiency: A new factor in diabetic neuropathy. Journal of the American Podiatric Medical Association, 68, 646-653.